Literature DB >> 20601184

The bacterial extract OM-85 BV protects mice against influenza and Salmonella infection.

Wolfgang G Bessler1, Ulrich Vor dem Esche, Noel Masihi.   

Abstract

The bacterial extract OM-85 BV has been shown to provide protection against recurrent respiratory infections. We here investigated its efficacy against viral and bacterial infections in murine models. We first evaluated the role of OM-85 BV protecting from an A/PR/8/34 (H1N1) influenza virus infection. In a group treated with 1.75 mg/mouse OM-85 BV all animals survived, compared to 70% in the untreated control group and a group treated with a lower dosage. In addition, the appearance of clinical signs was delayed, their intensity was decreased, and they disappeared faster; also a marked increase in the influenza hemagglutination inhibition antibody level was observed. Since bacterial infections often superimpose viral lung infections, we also investigated on the protection of mice from a Salmonella typhimurium infection after the oral administration of OM-85 BV. Here, 100% of the OM-85 BV treated animals survived compared to 58% of the untreated control group. The mechanism of protection was further investigated: OM-85 BV acts, on the one hand, as an immunogen: the repeated administration of OM-85 BV induced a marked increase in serum antibody levels recognizing pathogenic bacterial strains. On the other hand, the extract acts as a stimulator of the nonspecific macrophage, monocyte, dendritic cell, and granulocyte response. Our findings demonstrate the antimicrobial activity of OM-85 BV against infections, as also has been shown in clinical studies. (c) 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20601184     DOI: 10.1016/j.intimp.2010.06.009

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  11 in total

1.  Critical Adverse Impact of IL-6 in Acute Pneumovirus Infection.

Authors:  Caroline M Percopo; Michelle Ma; Todd A Brenner; Julia O Krumholz; Timothy J Break; Karen Laky; Helene F Rosenberg
Journal:  J Immunol       Date:  2018-12-21       Impact factor: 5.422

2.  Bacterial lysates improve the protective antibody response against respiratory viruses through Toll-like receptor 4.

Authors:  Silvina Coviello; Vera Wimmenauer; Fernando P Polack; Pablo M Irusta
Journal:  Hum Vaccin Immunother       Date:  2014-11-19       Impact factor: 3.452

3.  Broncho Vaxom (OM-85) modulates rhinovirus docking proteins on human airway epithelial cells via Erk1/2 mitogen activated protein kinase and cAMP.

Authors:  Michael Roth; Christian Pasquali; Daiana Stolz; Michael Tamm
Journal:  PLoS One       Date:  2017-11-28       Impact factor: 3.240

4.  OM-85 is an immunomodulator of interferon-β production and inflammasome activity.

Authors:  A T Dang; C Pasquali; K Ludigs; G Guarda
Journal:  Sci Rep       Date:  2017-03-06       Impact factor: 4.379

5.  Evidence that a primary anti-viral stimulation of the immune response by OM-85 reduces susceptibility to a secondary respiratory bacterial infection in mice.

Authors:  Giovanni A Rossi; Wolfgang Bessler; Stefania Ballarini; Christian Pasquali
Journal:  Ital J Pediatr       Date:  2018-09-26       Impact factor: 2.638

6.  Nonspecific immunomodulators for recurrent respiratory tract infections, wheezing and asthma in children: a systematic review of mechanistic and clinical evidence.

Authors:  Susanna Esposito; Manuel E Soto-Martinez; Wojciech Feleszko; Marcus H Jones; Kun-Ling Shen; Urs B Schaad
Journal:  Curr Opin Allergy Clin Immunol       Date:  2018-06

7.  Impact of OM-85 Given during Two Consecutive Years to Children with a History of Recurrent Respiratory Tract Infections: A Retrospective Study.

Authors:  Susanna Esposito; Sonia Bianchini; Ilaria Polinori; Nicola Principi
Journal:  Int J Environ Res Public Health       Date:  2019-03-25       Impact factor: 3.390

Review 8.  Trained Immunity-Based Vaccines: A New Paradigm for the Development of Broad-Spectrum Anti-infectious Formulations.

Authors:  Silvia Sánchez-Ramón; Laura Conejero; Mihai G Netea; David Sancho; Óscar Palomares; José Luis Subiza
Journal:  Front Immunol       Date:  2018-12-17       Impact factor: 7.561

9.  A randomized, placebo-controlled, double-blinded, single-centre, phase IV trial to assess the efficacy and safety of OM-85 in children suffering from recurrent respiratory tract infections.

Authors:  Susanna Esposito; Sonia Bianchini; Samantha Bosis; Claudia Tagliabue; Ilaria Coro; Alberto Argentiero; Nicola Principi
Journal:  J Transl Med       Date:  2019-08-23       Impact factor: 5.531

10.  Trained immunity induction by the inactivated mucosal vaccine MV130 protects against experimental viral respiratory infections.

Authors:  Paola Brandi; Laura Conejero; Francisco J Cueto; Sarai Martínez-Cano; Gillian Dunphy; Manuel J Gómez; Carlos Relaño; Paula Saz-Leal; Michel Enamorado; Ana Quintas; Ana Dopazo; Joaquín Amores-Iniesta; Carlos Del Fresno; Estanislao Nistal-Villán; Carlos Ardavín; Antonio Nieto; Miguel Casanovas; José Luis Subiza; David Sancho
Journal:  Cell Rep       Date:  2022-01-04       Impact factor: 9.995

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.